Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 148 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 24 Gy Clear all
Recruiting Phase 2 Interventional

Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)

NCT06305715
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Radiation Therapy, Targeted TKI therapy
Device · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Sep 7, 2026, 5:53 AM EDT
Terminated Phase 2 Interventional Results available

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

NCT03490760
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas
Interventions
Durvalumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 11, 2023 · Synced Sep 7, 2026, 5:53 AM EDT
Recruiting Phase 1 Interventional

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

NCT02390518
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer

NCT00091390
View directory record Official record
Conditions
Prostate Cancer
Interventions
High Dose brachytherapy boost, External beam radiotherapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
12
States / cities
Burbank, California • Inglewood, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2020 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)

NCT02221739
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Ipilimumab, Radiotherapy (IMRT or 3-D CRT)
Drug · Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 2 Interventional

Induction Chemotherapy Followed by Cetuximab and Radiation Therapy for Head and Neck Cancer

NCT01467115
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Radiotherapy, Leucovorin, Cetuximab, Filgrastim, Erythropoetin, Cisplatin, Fluorouracil, Docetaxel
Radiation · Drug · Biological
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 7, 2026, 5:53 AM EDT
Terminated Phase 2 Interventional Results available

Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer

NCT01354951
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prostate Biopsy, Focal Brachytherapy , Assessment of QOL
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
New Hyde Park, New York • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Not applicable Interventional

SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

NCT02986867
View directory record Official record
Conditions
Urothelial Carcinoma, Melanoma, Cervical Carcinoma in Situ
Interventions
SAbR Treatment of Lesions
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Not applicable Interventional Results available

(SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas

NCT01949506
View directory record Official record
Conditions
Stage IV Adult Soft Tissue Sarcoma, Sarcoma,Soft Tissue
Interventions
SBRT
Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

NCT02296684
View directory record Official record
Conditions
Cancer of Head and Neck, Head and Neck Cancer, Neoplasms, Head and Neck, Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head and Neck
Interventions
MK-3475 (neoadjuvant), Surgery, Intensity modulated radiation therapy, Image-guided radiation therapy, Cisplatin, MK-3475 (adjuvant), Peripheral blood
Biological · Procedure · Radiation + 1 more
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer

NCT01490749
View directory record Official record
Conditions
Esophageal Cancer, Neoplasms, Esophageal
Interventions
RAD001, XELOX, Carboplatin, Radiation
Drug · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional

Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)

NCT01469247
View directory record Official record
Conditions
Brain Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone

NCT00678158
View directory record Official record
Conditions
Metastatic Disease
Interventions
intensity modulated radiation therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 7, 2026, 5:53 AM EDT
Terminated Phase 1 Interventional

CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

NCT05325281
View directory record Official record
Conditions
Pancreas Adenocarcinoma
Interventions
CPI-613® (Dose level -1.0 250 mg/m^2), CPI-613® (Dose level 1.0 500 mg/m^2), CPI-613® (Dose level 2.0 1,000 mg/m^2), CPI-613® (Dose level 3.0 1,500 mg/m^2), CPI-613® Maximum Tolerated Dose (MTD), Gemcitabine, Intensity-modulated Radiation Therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 7, 2026, 5:53 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy

NCT03424850
View directory record Official record
Conditions
Prostate Cancer, Prostate Neoplasm
Interventions
HDR brachytherapy
Radiation
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 1Phase 2 Interventional

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

NCT00660218
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
paclitaxel poliglumex, cetuximab, radiation therapy (IMRT or 3D-CRT)
Drug · Biological · Radiation
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2021 · Synced Sep 7, 2026, 5:53 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

NCT02581384
View directory record Official record
Conditions
Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos, Renal Tumor, Rhabdoid Tumor, Clear Cell Renal Cell Carcinoma, Sarcoma, Sarcoma, Ewing, Soft Tissue Sarcoma
Interventions
Stereotactic Body Radiotherapy (SBRT)
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 7, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

NCT00004054
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, estramustine phosphate sodium, etoposide, flutamide, paclitaxel, Luteinizing hormone releasing hormone [LHRH] agonist, Radiation therapy, warfarin
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older · Male only
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2013
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Concord, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2020 · Synced Sep 7, 2026, 5:53 AM EDT
Recruiting Phase 1 Interventional

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT05967416
View directory record Official record
Conditions
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
Interventions
SIRPant-M, External-beam radiotherapy (XRT)
Biological · Radiation
Lead sponsor
SIRPant Immunotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Duarte, California • Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 7, 2026, 5:53 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma

NCT04792073
View directory record Official record
Conditions
Merkel Cell Carcinoma
Interventions
Avelumab, Comprehensive Ablative Radiation Therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Sep 7, 2026, 5:53 AM EDT
Terminated Not applicable Interventional Results available

Renal Denervation in Patients With Uncontrolled Blood Pressure

NCT01968785
View directory record Official record
Conditions
Blood Pressure
Interventions
Radiation Dose 25 Gy, Radiation Dose 50 Gy
Radiation
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 7, 2026, 5:53 AM EDT
Recruiting Phase 2 Interventional

Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

NCT03808337
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Non-Small Cell Lung Carcinoma
Interventions
Stereotactic Body Radiotherapy/SBRT, Systemic Therapy/Standard of Care
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
12
States / cities
San Carlos, California • Hartford, Connecticut • Norwalk, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 7, 2026, 5:53 AM EDT
Terminated Phase 3 Interventional Results available

Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer

NCT00004859
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, paclitaxel, thalidomide, radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
589 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
235
States / cities
Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Sep 7, 2026, 5:53 AM EDT
Terminated Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00119366
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Radiation · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
16 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 7, 2026, 5:53 AM EDT